Intersect ENT to Participate at Upcoming Investor Conferences
Intersect ENT, a leader in ENT medical technology, announced participation in two investor conferences. The first is the Bank of America Securities 2021 Virtual Health Care Conference on May 12, where CEO Tom West and CFO Randy Meier will join a fireside chat at 3:30 p.m. ET. The second event is Berenberg Corporate Access 2021 on May 18, comprising investor one-on-one meetings. Intersect ENT focuses on innovative steroid-releasing implants aimed at enhancing patient care and has expanded its offerings through the acquisition of Fiagon AG Medical Technologies.
- None.
- None.
Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that management will participate in the following upcoming investor conferences:
-
Bank of America Securities 2021 Virtual Health Care Conference
Tom West, President & Chief Executive Officer, and Randy Meier, Executive Vice President & Chief Financial Officer, will participate in a fireside chat at 3:30 p.m. ET / 12:30 p.m. PT on Wednesday, May 12, 2021.
A live webcast of the fireside chat at the Bank of America Securities 2021 Virtual Health Care Conference can be accessed by visiting the "Investor Relations" page of the Company's website at www.intersectENT.com. A replay will be available on the Company's website following the event.
-
Berenberg Corporate Access 2021
Management will participate in investor 1x1 meetings on Tuesday, May 18, 2021.
About Intersect ENT
Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. The Company’s steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company’s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings, including the VENSURE sinus balloon, that complement the Company's PROPEL® and SINUVA® sinus implants and extend its geographic reach.
For additional information on the Company or the products including risks and benefits please visit www.IntersectENT.com. For more information about PROPEL® (mometasone furoate) sinus implants and SINUVA® (mometasone furoate) sinus implant, please visit www.PROPELOPENS.com and www.SINUVA.com.
Intersect ENT®, PROPEL® and SINUVA®, are registered trademarks of Intersect ENT, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210507005542/en/
FAQ
What is the date of the Bank of America Securities 2021 Virtual Health Care Conference for Intersect ENT?
Who from Intersect ENT will speak at the Bank of America conference?
What is the purpose of the Berenberg Corporate Access 2021 event?
What products does Intersect ENT focus on?
When was Fiagon AG Medical Technologies acquired by Intersect ENT?
